$NKTX

$1.70 -$0.13 (7.1%) Close

$NKTX Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$NKTX Management Team

Dr. Ali Behbahani

Independent Chairman of the Board

Age 49

Compensation $204.9K USD

Sex Male

Dr. Nadir Mahmood

President

Principal Financial Officer

Age 45

Compensation $3.336M USD

Sex Male

Mr. Paul Hastings

Chief Executive Officer

Director

Age 65

Compensation $3.985M USD

Sex Male

Dr. Shawn Rose

Chief Medical Officer and Head of Research and Development

Age -

Compensation -

Sex Male

Name / Title	Age	Compensation	Sex
Dr. Ali Behbahani Independent Chairman of the Board	49	$204.9K USD	Male
Dr. Nadir Mahmood President Principal Financial Officer	45	$3.336M USD	Male
Mr. Paul Hastings Chief Executive Officer Director	65	$3.985M USD	Male
Dr. Shawn Rose Chief Medical Officer and Head of Research and Development	-	-	Male

Board of Directors

From the proxy statement filed Apr 23, 2026

Directors

serving now

Independent

7 of 8

stated in the proxy

Average tenure

6.2 years

from year joined

CEO also chairs the board

Ali Behbahani

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
Ali Behbahani Board chair	50	2015 11 years	Independent	None stated	None stated	$154,789
Zachary Scheiner	49	2020 6 years	Independent	None stated	Lenz Therapeutics	Not stated
Michael Dybbs	51	2019 7 years	Independent	None stated	Sutro Biopharma, Inc.	Not stated
Simeon George	49	2020 6 years	Independent	None stated	None stated	$113,289
Leone Patterson	63	2020 6 years	Independent	None stated	Kalaris Therapeutics	$122,289
Paul J. Hastings CEO	66	2018 8 years	Not independent	None stated	enGene Holdings Inc.	Paid as CEO
Angela Thedinga	44	2022 4 years	Independent	None stated	None stated	$132,789
George Vratsanos	62	2024 2 years	Independent	None stated	None stated	Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

4 disclosed in the proxy filed Apr 23, 2026

Carnot Pharma, LLC (d/b/a RA Ventures)

affiliate of RA Capital, a greater than 5% stockholder of the Company

Approximately $152,000

since the beginning of the Company's fiscal year ending December 31, 2025

Consulting services for clinical operations, development, regulatory, and patient engagement, invoiced to the Company

Open in proxy

RA Capital Management, LP

entity of which director Zachary Scheiner is a Partner

$60,000,000

Purchased 3,000,000 shares of common stock and 3,000,031 pre-funded warrants in the March 2024 Offering

Open in proxy

Samsara BioCapital, LP

entity of which director Michael Dybbs is a Partner

$9,000,000

Purchased 900,000 shares of common stock in the March 2024 Offering

Open in proxy

SR One Capital Management, LP

$20,000,000

Purchased 2,000,000 shares of common stock in the March 2024 Offering

Open in proxy

Comments

Company Executives

$NKTX Management Team

Dr. Ali Behbahani

Dr. Nadir Mahmood

Mr. Paul Hastings

Dr. Shawn Rose

Board of Directors

Related-party transactions